Thyroid Cancer Trial, Recruiting NCT06855680 Sponsor: Royal Marsden NHS Foundation Trust Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT06855680
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People of any gender
  • People diagnosed with a low-risk, slow-growing type of thyroid cancer (called papillary or follicular thyroid carcinoma) where the tumour measures between 1 and 4 centimetres — diagnosed either by a needle biopsy test before surgery, or confirmed after a partial thyroid removal operation
  • People who can speak, read, and write in English

Who may not be able to join:

  • People whose thyroid cancer cells look more aggressive or unusual under a microscope (such as poorly differentiated, tall cell, columnar cell, Hurthle cell, or solid variant types)
  • People whose thyroid cancer appears in more than one spot, on both sides of the thyroid, has grown outside the thyroid gland, or has spread into nearby nerves or blood vessels
  • People whose thyroid cancer has spread to nearby lymph nodes or to other parts of the body
  • People whose thyroid cancer is linked to a family history of the condition
  • People who are currently pregnant or breastfeeding
  • People who have an overactive or underactive thyroid and are already being considered for surgery for that condition
  • People who have also been diagnosed with a different type of thyroid or parathyroid condition, such as medullary thyroid cancer, anaplastic thyroid cancer, thyroid lymphoma, or parathyroid disease
  • People who have previously had thyroid surgery for any reason other than the partial thyroid removal related to their current cancer diagnosis
  • People who have a cognitive impairment or a mental health condition that would prevent them from giving informed consent to participate
  • People who are not able to read, write, and speak in English

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02073528171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Royal Marsden NHS Foundation Trust
Registry
ClinicalTrials.gov
Start date
19 June 2024
Est. completion
1 October 2025

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Recruitment rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov